Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class ...

Disparities in Utilization of Immune Checkpoint Inhibitor Therapy Among Older Patients With Advanced Non–Small Cell Lung Cancer: A SEER-Medicare Analysis Adults with previously treated ...